Notably, lenalidomide inhibits MALT1-mediated BCL10 cleavage (an indicator of CBM complex activation) and suppresses NFκB activity in non-GCB DLBCL cell lines (22). This evidence concerns the gene BCL10 and diffuse large B-cell lymphoma.